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Summary
Purpose:  Topiramate  (TPM)  is  known  to  cause  language  impairment  in  healthy  volunteers  and
patients  with  epilepsy.  We  assessed  the  effects  of  TPM  on  functional  language  networks  in  both
patients  with  focal  epilepsies  and  healthy  controls  using  functional  magnetic  resonance  imaging
(fMRI).
Methods:  We  obtained  fMRI  data  in  24  controls  and  35  patients  with  frontal  lobe  epilepsy  using
a simple  verbal  ﬂuency  (VF)  paradigm.  Eight  of  the  35  patients  were  treated  with  TPM  in
polytherapy.  We  compared  cognitive  task  related  activations  and  de-activations  in  patients
taking TPM  with  patients  taking  other  AEDs  and  healthy  controls.  In  a  longitudinal  pilot  study
with VF-fMRI  paradigm,  we  studied  two  patients  with  focal  epilepsies  twice,  prior  to  starting
and on  stable  doses  of  TPM,  two  patients  twice,  before  and  after  tapering  TPM  completely  and
two healthy  controls  twice,  before  and  after  single  doses  of  200  mg  TPM.
Key ﬁndings:  Cross  sectional  analyses  of  VF-fMRI  showed  a  reduction  in  the  task-related  deac-
tivation of  the  default  mode  network  (DMN)  in  patients  taking  TPM.  The  longitudinal  study
corroborated  these  ﬁndings  as  both  chronic  administration  and  a  single  dose  of  TPM  were  asso-
ciated with  impaired  categorical  verbal  ﬂuency  and  disruption  of  task-related  deactivations.
Signiﬁcance:  Similar  neuropsychological  and  fMRI  ﬁndings  in  patients  and  healthy  controls  indi-
cate a  speciﬁc  effect  of  TPM  in  default  mode  network  areas  that  may  be  essential  components
of the  language  network.  Our  pr
nitive processing  during  languag
effects of  AEDs  on  cognitive  bra
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Introduction
A  major  concern  when  selecting  appropriate  anti-epileptic
drug  (AED)  treatment  is  adverse  effects  on  cognition  and
behavior  (Thompson  et  al.,  2000;  Loring  et  al.,  2011).
Expressive  language  difﬁculties,  particularly  word-ﬁnding
and  dysnomia  as  well  as  working  memory  impairment  (Lee
et  al.,  2003;  Szaﬂarski  and  Allendorfer,  2012),  are  rather
speciﬁc  for  topiramate  (TPM),  and  rarely  seen  with  other
AED.  These  effects  have  been  described  not  only  in  patients
with  epilepsy,  but  also  in  people  with  migraine  (De  et  al.,
2008).  However,  the  mechanisms  involved  are  poorly  under-
stood  and  there  is  no  clinical  test  available  that  reliably
predicts  who  is  at  risk  of  developing  side-effects  (Brandes
et  al.,  2004;  Loring  et  al.,  2011).  FMRI  revealed  decreased
activation  of  prefrontal  cortex  in  response  to  a  verbal
task  in  TPM-treated  epilepsy  patients  (Jansen  et  al.,  2006;
Szaﬂarski  and  Allendorfer,  2012)  while  withdrawal  of  TPM
was  associated  with  improved  cognitive  measures  sensitive
to  frontal  lobe  functioning  (Kockelmann  et  al.,  2003).  A
recent  study  demonstrated  a  dose-related  effect  of  TPM
on  language  fMRI,  affecting  areas  of  resting  state  network
(Szaﬂarski  and  Allendorfer,  2012)  in  patients  with  TLE.
In  this  study  we  aimed  to  investigate  regional  effects
of  TPM  on  cognitive  fMRI  activation  patterns  and  used  two
approaches.  First,  we  analyzed  fMRI  studies  in  a  cohort  of
frontal  lobe  epilepsy  (FLE)  patients  with  regards  to  AEDs
taken;  second,  in  a  prospective,  open-label  pilot  study,
we  compared  cognitive  task  related  activations  and  de-
activations  in  two  healthy  controls  who  received  single  doses
of  200  mg  TPM,  and  four  patients  who  either  started  or
stopped  TPM  for  clinical  reasons.
Methods
For  the  cross-sectional  study  we  obtained  verbal  ﬂuency  (VF)
fMRI  and  neuropsychological  data  of  35  patients  (15  females,
age:  median  33  —  interquartile  range  [IQR]:  18  years)  with
either  cryptogenic  frontal  lobe  epilepsy  (FLE)  or  FLE  due  to
focal  cortical  dysplasia  (17  right-sided  frontal  focus,  13  left-
sided  and  5  uncertain  frontal  lobe  lateralization).  Patients
with  large  lesions  were  excluded  from  this  study.  Patients
were  recruited  from  the  epilepsy  clinics  at  our  center  (Lon-
don,  UK)  (Vollmar  et  al.,  2011).  Twenty-four  healthy  controls
(13  females,  age:  median  30  —  IQR:  7  years)  without  a  history
of  epilepsy  or  other  neurological  condition  were  included  for
comparison.  Eight  of  the  35  patients  were  treated  with  TPM
(dose  range:  50—500  mg;  median  187.5  mg)  given  in  poly-
therapy,  the  remaining  27  patients  formed  the  other-AED
group.  Clinical  data  are  displayed  in  Table  1A.
For  the  longitudinal  pilot  study,  four  patients  with  focal
epilepsies  (1  temporal  lobe  epilepsy  (TLE)  and  3  extra-TLE)
were  studied  as  part  of  their  pre-surgical  assessment  with
the  same  VF-fMRI  paradigm  (Bonelli  et  al.,  2011).  FMRI  was
acquired  in  two  patients  prior  to  starting  TPM  (TPM-off),  and
repeated  once  patients  were  taking  a  working  dose  (TPM-
on),  and  in  two  patients  before  withdrawal  (TPM-on)  and
again  after  complete  cessation  (TPM-off).  These  changes
were  made  for  clinical  reasons.  In  addition,  two  healthy
male  controls  were  studied  before  (TPM-off)  and  3  h  after
a  single  oral  dose  of  200  mg  TPM  (TPM-on).
R
L
c251
The  study  was  approved  by  the  Research  Ethics  Commit-
ee  of  the  UCL  Institute  of  Neurology  and  UCL  Hospitals.
Informed  consent  was  obtained  from  each  participant.)
All  subjects  underwent  a  brief  neuropsychological  evalu-
tion  of  verbal  ﬂuency  (letter  S  and  category)  and  backwards
igit  Span  in  close  proximity  to  their  fMRI  scans  (clinical  data
re  displayed  in  Table  1B).  Neuropsychological  test  perfor-
ance  was  compared  using  Wilcoxon  tests.
All  fMRI  studies  were  performed  on  a  3T  GE  Excite  HDx
canner  as  described  previously  (Vollmar  et  al.,  2011),  with
cquisition  of  gradient-echo  planar  T2*-weighted  images
TE  =  25  ms,  TR  =  2500  ms),  providing  blood  oxygenation
evel-dependent  (BOLD)  contrast.  The  VF-fMRI  paradigm
onsisted  of  a  5.5  min  blocked  design  with  alternating
eriods  of  30  s of  a  task  (subjects  requested  to  covertly
enerate  different  words  beginning  with  a  visually  pre-
ented  letter,  A,  S,  W,  D  and  E)  and  baseline  (cross-hair
xation)  (Bonelli  et  al.,  2011).  We  analyzed  the  fMRI  data
ithin  the  framework  of  the  general  linear  model  using
PM5  (http://www.ﬁl.ion.ucl.ac.uk/spm5),  including  two
evel  random  effects  analysis.  Prior  to  analysis,  the  data
as  realigned  and  spatially  normalized  (using  a  T1-weighted
tructural  image  co-registered  to  the  time-series  to  deter-
ine  the  parameters).  The  ﬁrst  level  model  included  the
ask  blocks  with  the  baseline  coded  implicitly  and  the  six
ovement  regressors.  The  second  level  was  used  to  test:
)  VF  activations  and  deactivations  in  each  group  (TPM,
other-AEDs,  controls);
) Changes  in  BOLD  signal  associated  to  different  TPM
doses.
Activations  are  reported  at  a  threshold  of  p  <  0.05
corrected  for  multiple  comparisons  with  false  discovery
ate  method).  Deactivations  are  reported  with  threshold
p  <  0.001)  uncorrected  for  multiple  comparisons  due  to  the
reliminary  nature  of  this  work.
) FMRI  data  was  analyzed  with  a  ﬁxed-effect  statistical
model  to:
)  Identify  activation  and  deactivations  for  VF  for  each
acquisition  (TPM-on/-off);
)  Compare  the  differences  in  deactivations  between  the
two  acquisitions  (TPM-on  versus  TPM-off)  for  each  sub-
ject;
)  To  investigate  commonalities  amongst  subjects  using  a
conjunction  analysis  (Friston  et  al.,  2005).
Resulting  maps  were  thresholded  at  p  <  0.001,  uncor-
ected  for  multiple  comparisons.
Patients  performed  a  letter  ﬂuency  test  outside  the  scan-
er,  in  which  they  were  instructed  to  say  as  many  words  as
ossible  starting  with  the  letter  ‘‘S’’  in  1  min  (Bonelli  et  al.,
011).  For  correlation  analysis  the  individual  fMRI  maps  were
egressed  against  the  TPM  doses.  To  compare  clinical  and
europsychological  scores  we  used  Mann—Whitney  U-test.esults
etter  ﬂuency  ‘‘S’’  was  reduced  for  patients  taking  TPM
ompared  to  other  FLE  patients  (p  =  0.053).  A  single  dose  of
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Table  1  Clinical  data  from  cross-sectional  study  (A)  are  displayed  as  median  (interquartile  range);  the  longitudinal  pilot  study
(B) data  shows  individual  clinical  parameters  and  neuropsychological  scores  from  outside  scanner  acquired  on  and  off  TPM.
(A)  Cross-sectional  data
Controls  (24)  TPM  (8)  Other  AEDS  (27)
Age  (years)  30  (7)  30  (13)  35  (20)
Gender (f/m)  13/11  4/4  11/16
NART-IQ 111  (10.5)  96  (12)  97  (14)
Letter ﬂuency  ‘‘S’’  15.5  (7)  9  (8)  10  (4)
Categorical ﬂuency  23.5  (4)  17  (10)  18  (9)
Age of  onset  —  7.5  (3)  9  (6)
Duration (years) —  24.5  (14)  21  (16)
Seizure frequency  (partial/month) —  15  (25.5) 20  (116)
Speciﬁc AED  dose  (mg/day)  —  187.5  (175)  —
Polytherapy  (%)  —  100%  100%
Number of  AEDs  —  3  (1.5)  3  (1)
(B) Longitudinal  pilot  study
Subject  1  Subject  2  Subject  3  Subject  4  Subject  5  Subject  6
Age  35  23  22  40  28  56
Age of  onset  (years)  6  4  21  9  —  —
Duration (years)  29  19  1  31  —  —
Classiﬁcation  FLE  Occipital
Tuberous
FLE  TLETemporal  Control  Control
MRI Normal  Sclerosis  Normal  Resection  Control  Control
Type of  intervention  ON—OFF  ON—OFF  OFF—ON  OFF—ON  Acute  Acute
TPM dose  (mg)  200  300  150  325  200  200
Serum levels  (mol/L)
Range  6—74  —  —  —  —  8  0.48
On Off  On  Off  On  Off  On  Off  On  Off  On  Off
Letter  ﬂuency  8  16  12  22  19  14  3  11  23  37  22  22
Categorical ﬂuency  10  13  16  31  26  35  9  11  13  45  16  22
Digit backwards —  7  2  4  4  7  4  5  11  14  9  7
—  
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PM  led  to  a  reduction  of  letter  ﬂuency  ‘‘S’’  (median  reduc-
ion  42%,  IQR  50%,  p  =  0.078),  category  ﬂuency  (median  26%,
QR  25%,  p  =  0.028)  and  backwards  Digit  Span  Score  (median
4%,  IQR  22.5%,  p  =  0.17).
For  the  cross-sectional  study,  group  maps  showed  task-
elated  activations  within  the  left  frontal  cortex  for  controls
nd  patients  with  and  without  TPM  (Fig.  1A,  C  and  E).
onversely,  tasks  related  deactivations  were  observed  in
ontrols  and  FLE  taking  other  AED,  but  no  signiﬁcant
eactivations  were  identiﬁed  in  TPM  group  (Fig.  1D—F).
urthermore,  activity  in  the  DMN  areas  during  the  task
orrelated  with  an  increasing  dose  of  TPM  (R  =  0.97)
Fig.  1G—I).
For  the  longitudinal  pilot  study,  fMRI  analysis  showed  a
on-signiﬁcant  decrease  in  activation  of  normal  language
reas  during  the  TPM-on  condition.  Task-related  deacti-
ations  revealed  the  typical  default  mode  network  (DMN)
uring  the  TPM-off  scans  (areas  in  blue  in  Fig.  2  (patients
—D,  controls  E  and  F),  but  not  during  the  TPM-on  scan  (red
n  Fig.  2).  For  each  individual,  the  differences  between  the
eactivation  maps  on—off  topiramate  were  mainly  located
f
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n  areas  of  the  DMN,  i.e.  precuneus,  frontal  pole  and
arietal  lobes.  Conjunction  analysis  showed  that  the  com-
on  areas  of  difference  across  the  6  subjects  are  within  the
MN  (Fig.  2G—I).
iscussion
n  subjects  taking  topiramate,  we  detected  a  failure  to
eactivate  the  DMN  during  verbal  ﬂuency  fMRI,  even  after
 single  high  dose  or  during  chronic  treatment.  This
mpaired  deactivation  was  correlated  with  an  increasing
osage  of  TPM,  indicating  a  possible  speciﬁc  effect  of  TPM
n  cognitive  (language)  networks.  Appropriate  deactiva-
ion  of  the  DMN  during  cognitive  tasks  is  necessary  for
he  correct  performance.  Our  ﬁndings  are  in  keeping  with
 recent  study  of  TLE  patients  showing  deactivations  in
rontal  lobes  related  to  increased  doses  of  TPM  (Szaﬂarski
nd  Allendorfer,  2012).  In  addition,  by  testing  the  same
ubjects  with  and  without  TPM  effect  in  a  more  pow-
rful  longitudinal  analysis,  we  could  replicate  the  initial
Topiramate  and  cognitive  fMRI  253
Figure  1  FMRI  results  (cross-sectional  analysis).  Red  maps  represent  activations  and  blue  maps  represent  deactivations.  (A  and
B) controls,  (C  and  D)  other  FLE  patients  and  (E  and  F)  TPM  patients.  The  reduced  area  of  deactivation  in  TPM-group  (F)  suggests  a
speciﬁc effect  of  this  AED  on  DMN  activity.  (G)  and  (H)  are  correlational  analysis,  showing  the  activation  in  precuneus  correlated
positively with  increasing  TPM  dosage.  (I)  Correlation  of  fMRI  activation  for  verbal  ﬂuency  and  TPM  dosages  at  peak  voxel  in
o
r
a
l
D
a
oprecuneus.
ﬁndings  from  our  cross-sectional  analysis  that  the  fail-
ure  to  deactivate  the  DMN  was  associated  with  the  TPM
treatment.
In  addition,  patients  presented  with  decreased  activation
of  normal  language  network  fMRI  in  relation  to  a  reduction  of
neuropsychological  language  scores,  for  both  TPM  and  other
AEDs,  in  accordance  with  previous  studies  (Szaﬂarski  and
Allendorfer,  2012;  Jansen  et  al.,  2006).One  possible  mechanism  directly  associated  with  the
dysfunction  of  DMN  relates  to  the  inhibition  of  carbonic
anhydrase  by  TPM  (similarly  to  acetazolamide),  which
causes  an  increased  cerebral  blood  ﬂow  without  increasing
p
a
e
oxygen  consumption,  resulting  in  an  intensiﬁcation  of  the
esting  bold  signal  and  attenuation  of  the  bold  signal  during
ctivation  (Bruhn  et  al.,  1994).
The  dysfunction  of  DMN  and  the  consequent  disruption  of
anguage  processing  are  in  agreement  with  the  view  of  the
MN  being  closely  linked  to  networks  of  semantic  processing
nd  other  language  functions  (Binder  et  al.,  2009).  We
bserved  these  TPM  effects  in  both  temporal  and  extratem-
oral  lobe  patients  (TPM  add-on)  and  healthy  controls  (after
 single  dose),  which  provides  evidence  for  a  TPM  speciﬁc
ffect  in  default  mode  areas,  regardless  of  treatment  with
ther  AEDs  or  underlying  pathology.
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Figure  2  FMRI  results  (longitudinal  pilot  study).  Red  maps  represent  deactivations  from  TPM-on  status  and  blue  maps  repre-
sent deactivations  from  TPM-off.  The  reduced  deactivations  in  red  suggest  a  speciﬁc  effect  of  TPM  in  the  DMN.  (A—D)  Patients;
(E—F) healthy  controls.  (G)  Results  from  the  conjunction  analysis,  illustrating  the  common  areas  from  6  difference  maps,  including
precuneus,  bi-parietal  and  frontal  areas.
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We  cannot  exclude,  though,  from  this  limited  data  that
other  AEDs  have  a  similar  effect  on  default  mode  network,
although  we  did  not  observe  this  failure  to  de-activate  for
patients  treated  with  carbamazepine  or  levetiracetam  (data
not  shown).
Conclusions
Our  preliminary  data  suggest  that  fMRI  may  be  useful  to
detect  subtle  drug  effects  on  cognitive  networks.  Currently,
it  remains  unclear  why  some  patients  develop  side-effects
on  AEDs,  and  others  do  not.  Beyond  the  common  dose-
related  adverse  effects,  there  are  no  reliable  predictors
of  adverse  effects  of  AED  treatment.  In  this  context,  fMRI
investigations  could  help  to  stratify  patients  for  speciﬁc
treatments  allowing  individualization  of  treatments  and
determining  where  in  the  brain  the  effect  of  AEDs  on  cog-
nition  occurs.  Such  studies  would  be  applicable  to  a  broad
range  of  CNS  diseases  with  TPM  also  being  an  effective  or
prophylactic  treatment  for  headaches  and  addiction.  Larger
longitudinal  studies  in  both  patients  and  controls  will  be
necessary  to  assess  the  speciﬁc  inﬂuence  of  TPM  and  other
anti-epileptic  medication  on  cognitive  function.
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